A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine

Inclusion Criteria: * Participants at least 18 years of age at baseline visit * Signed written informed consent * New initiation with dupilumab or in whom treatment with dupilumab was started within the last 7 days for moderate to severe prurigo nodularis according to the prescribing information/Summary of Product Characteristics (SmPC) * Patients who received the initial diagnosis of PN Exclusion Criteria: * Patients who have a contraindication to dupilumab according to the current prescribing information label/SmPC * Patients who have been treated for more than 7 days with dupilumab * Any acute or chronic condition that, in the treating physician´s opinion, would limit the patient´s ability to complete questionnaires or to participate in this study or impact the interpretation of the results * Participation in an ongoing interventional or observational study that might, in the treating physician´s opinion, influence the assessments for the current study The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.